OCUL250117C17500
- 0.06
- 0.000.00%
Ocular Therapeutix Newsroom
EyePoint Initiated at Buy by Citi on WAMD Drug Potential
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $18
Ocular Therapeutix (OCUL) Receives a Buy From Bank of America Securities
Investors Might Be Losing Patience for Ocular Therapeutix's (NASDAQ:OCUL) Increasing Losses, as Stock Sheds 12% Over the Past Week
Possible Bearish Signals With Ocular Therapeutix Insiders Disposing Stock
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Ocular Therapeutix, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference in January 2025
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $21
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Baxter International (BAX) and Ocular Therapeutix (OCUL)
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Ocular Therapeutix Analyst Ratings
Promising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial Valuation
Ocular Therapeutix Initiates First Registrational Trial SOL-1 for AXPAXLI in Wet AMD With Topline Data Expected Q4 2025
Express News | Ocular Therapeutix Inc -Topline Clinical Data From Sol-1 Expected in Q4 2025
Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1
Insider Sale: Chief Scientific Officer of $OCUL (OCUL) Sells 2,948 Shares
Ocular Therapeutix to Participate in December Investor and Scientific Conferences
Swelling Losses Haven't Held Back Gains for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Since They're up 302% Over 1 Year
Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22